A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) (GZ402673-OBS13434)

24/09/2014
04/08/2026
EU PAS number:
EUPAS7346
Study
Ongoing

ENCePP Code of conduct

No
Data sources

Data sources (types)

Administrative healthcare records (e.g., claims)
Disease registry
Other

Data sources (types), other

Prospective patient-based data collection, Danish MS registry (DMSR), Belgian MS registry (BELTRIMS), social security databases of Belgium (AIM-IMA), reginal healthcare databases of Lombardy (Italy) (HUCD) are participating to the external comparison cohort study.
Use of a Common Data Model (CDM)

CDM mapping

No
Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown
Data characterisation

Data characterisation conducted

No
Procedures
No information provided.